Year: 2016
Type: review
Abstract: Fragile X syndrome (FXS) is the most common inherited form of intellectual disability, and is the leading single-gene cause of autism spectrum disorders. It is due to a loss of the fragile X mental retardation protein, which leads to molecular, behavioral, and cognitive deficits in these patients. Improvements in our understanding of its pathophysiology have led to the development of numerous targeted treatments in FXS as highlighted by metabotropic glutamate receptor antagonists and gamma-Aminobutyric acid receptor modulators. This review will summarize relevant pre-clinical data and results from clinical trials in human subjects with FXS. It will also highlight upcoming studies and future directions for clinical trials as well.
Authors: Andrew Ligsay, Randi J Hagerman
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: diamond
Awards: G2183559457, UC Davis Clinical and Translational Science Center, MIND Institute Intellectual and Developmental Disabilities Research Center, G4096623411, G5178656058, G6931323045, UC Davis Clinical and Translational Science Center, G8340852147, G8397502294, Genotype-Phenotype Relationships in Fragile X Families
OpenAlex ID: W2507895118
